Association of MDR1 G2677T polymorphism and leukemia risk: Evidence from a meta-analysis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2191-2197

  Yan, Yulan ^a   Liang, Hongjie ^a   Xie, Li ^a   He, Yu ^a   Li, Meng ^a   Li, Ruolin ^a   Li, Shan ^a   Qin, Xue ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Leukemia; MDR1; Meta analysis; Polymorphism

Indexed keywords

AFRICA; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HOMOZYGOTE; HUMAN; LEUKEMIA; LYMPHATIC LEUKEMIA; MDR1 GENE; MYELOID LEUKEMIA; ONCOGENE; PRIORITY JOURNAL;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUKEMIA; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84899091237     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1291-0     Document Type: Article

References (43)

1. Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia. 2001;15:670-2.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.
3. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood. 2009;114:1053-62.
4. Du J, Lu C, Cui G, Chen Y, He J. DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis. Chin J Cancer Res. 2013;25:405-15.
5. Guo LM, Xi JS, Ma Y, Shao L, Nie CL, Wang GJ. ARID5B gene rs10821936 polymorphism is associated with childhood acute lymphoblastic leukemia: a meta-analysis based on 39,116 subjects. Tumour Biol. 2013doi: 10.1007/s13277-013-1097-0.
6. Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, et al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013;121:4366-76.
7. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS One. 2013;8:e60699.
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
9. He YZ, Hu X, Chi XS, Zhang YC, Deng XB, Wei MT, et al. Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis. Tumour Biol. 2013. doi: 10.1007/s13277-013-1085-4.
10. Pannucci NL, Li D, Sahay S, Thomas EK, Chen R, Tala I, et al. Loss of the xeroderma pigmentosum group b protein binding site impairs p210 BCR/ABL1 leukemogenic activity. Blood Cancer J. 2013;3:e135.
11. Gruhn B, Naumann T, Gruner D, Walther M, Wittig S, Becker S, et al. The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk Res. 2013;37(10):1200-7.
12. Kitamura T, Watanabe-Okochi N, Inoue D, Togami K, Uchida T, Kagiyama Y, et al. Molecular mechanisms underlying leukemic transformation of myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CML). Rinsho Ketsueki. 2012;53:734-9.
13. Li ZG, Jiao Y, Li WJ, Deng GR, Cui L, Gao C, et al. Hypermethylation of two CpG sites upstream of CASP8AP2 promoter influences gene expression and treatment outcome in childhood acute lymphoblastic leukemia. Leuk Res. 2013;37(10):1287-93.
14. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein - implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5:457-68.
15. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52:759-66.
16. Zintzaras E. Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:562-72.
17. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-8.
18. Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006;107:2850-7.
19. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002;13:1847-54.
20. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006;79:325-38.
21. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72:209-19.
22. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-43.
23. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112:2024-7.
24. Yan Q, Wajapeyee N. Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biol Ther. 2010;9:166-75.
25. Lv H, Du Z, Wang W, Zhao W, Wang Y, Hu S, et al. Multidrug resistance gene polymorphisms and childhood acute lymphoblastic leukemia correlation. Chin J Pediatr. 2012;50:692-6.
26. Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in egyptian chronic myeloid leukemia patients. Hematology. 2013. doi: 10.1179/1607845413Y.0000000102.
27. Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, et al. MDR-1 polymorphisms (G2677T and C3435T) in b-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol. 2011;28:1549-54.
28. Vivona D, Bueno CT, Lima LT, Hirata RD, Hirata MH, Luchessi AD, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012;48:132-6.
29. Semsei AF, Erdelyi DJ, Ungvari I, Kamory E, Csokay B, Andrikovics H, et al. Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res. 2008;32:1214-20.
30. Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev. 2007;16:1172-7.
31. Kaya P, Gunduz U, Arpaci F, Ural AU, Guran S. Identification of polymorphisms on the MDR1 gene among turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol. 2005;80:26-34.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
35. Zintzaras E. Variance estimation of allele-based odds ratio in the absence of Hardy-Weinberg equilibrium. Eur J Epidemiol. 2008;23:323-6.
36. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634-45.
37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
38. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
39. Yuan H, Li X, Wu J, Li J, Qu X, Xu W, et al. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem. 2008;15:470-6.
40. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large b-cell lymphoma. Oncology. 2005;68:422-31.
41. Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, et al. Mdr1 (c3435t) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10:62-9.
42. George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E. A single-nucleotide polymorphism in the mdr1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009;9:161-5.
43. Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213:140-5.